A bdominal obesity is associated with a number of important metabolic and cardiovascular abnormalities, including among others ectopic fat accumulation (including liver steatosis), insulin resistance, low-grade inflammation and increased oxidative stress, impaired glucose homeostasis, hypertriglyceridemia, low high-density lipoprotein cholesterol level, hypertension, and abnormalities of hemostasis, contributing to the increased risk of type 2 diabetes mellitus and cardiovascular diseases (ie, cardiometabolic risk).1 The hypertriglyceridemia associated with this condition involves metabolic abnormalities of all triglyceride-rich lipoproteins (chylomicrons, very-low density lipoproteins [VLDL], and their remnants) caused by a complex interplay between environmental factors, such as food intake and physical activity, and cumulative, multiple gene variants.2 Some factors may predominantly increase triglyceride-rich lipoprotein secretion as, for example, excessive food intake and insulin resistance. [3][4][5] Other factors, such as lipoprotein lipase (LPL), apolipoprotein E, and apolipoprotein A5 polymorphisms, may predominantly affect triglyceride-rich lipoprotein clearance either or both through transfer into less buoyant particles or through direct removal of the particle from the circulation.2 The present view is that hypertriglyceridemia associated with abdominal obesity stems from a combination of enhanced triglyceride-rich lipoprotein secretion with some impairment of clearance.
2
See accompanying article on page 2218In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Borén et al 6 report VLDL 1 triglyceride and apolipoprotein B100 kinetics in 46 (37 men and 9 women) middleaged, insulin-resistant subjects with abdominal obesity and mild hypertriglyceridemia (ie, fasting triglyceride between 1.7 and 4.5 mmol/L) or low high-density lipoprotein cholesterol. This study found VLDL fractional clearance rate to be a more important determinant of plasma triglycerides than VLDL secretion rate in subjects with abdominal obesity and mild dyslipidemia. The authors confirmed that the most important determinant of VLDL triglyceride and apolipoprotein B100 secretion rates was increased liver fat measured by 1 H-magnetic resonance spectroscopy, in accordance with previous studies. 7 Interestingly, plasma apolipoprotein CIII (apoCIII) level was the strongest predictor of VLDL 1 triglyceride and apolipoprotein B100 fractional clearance rate. This finding is also in line with a previous study showing a relatively strong inverse correlation between VLDL fractional clearance rate and VLDL to low-density lipoprotein (LDL) conversion rate and total plasma or VLDL apoCIII levels. 8,9 The relatively small influence of apolipoprotein E on VLDL clearance in subjects with abdominal obesity contrasts with the importance of apolipoprotein E for VLDL catabolism in healthy individuals.3,10 The contribution of apoCIII to hypertriglyceridemia in humans was directly demonstrated by the significant reduction of circulating VLDL...